Increased MT2-MMP expression in gastric cancer patients is associated with poor prognosis

被引:1
作者
Xu, Xiaoli
Chen, Lujun
Xu, Bin
Xie, Quanqin
Sun, Mingfen
Deng, Xu
Wu, Changping [1 ]
Jiang, Jingting
机构
[1] Soochow Univ, Affiliated Hosp 3, Dept Tumor Biol Treatment, Changzhou 213003, Jiangsu, Peoples R China
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY | 2015年 / 8卷 / 02期
基金
中国国家自然科学基金;
关键词
Membrane type-2 MMP; gastric cancer; prognosis; MATRIX METALLOPROTEINASES; ANGIOGENESIS; MATRIX-METALLOPROTEINASE-9; IDENTIFICATION; CELLS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that contribute to tumorigenesis and metastasis due to their ability to degrade the extracellular matrix (ECM) and basement membrane. In despite of many reports in other solid tumors, the role of membrane type-2 MMP (MT2-MMP) in gastric cancer (GC) remains to be elucidated. The aim of this study was to investigate MT2-MMP expression in human GC tissue microarray (TMA) samples using immunohistochemistry (IHC). We found that MT2-MMP expression in tumor tissues was significantly higher compared to peritumoral tissues (P < 0.01). However, there were no statistically significant differences between MT2-MMP expression and clinicopathological parameters. In addition, univariate and multivariate Cox regression analysis showed GC patients with high MT2-MMP expression have poor overall survival (OS) compared to patients with low MT2-MMP expression (P = 0.013, P = 0.040, respectively). In conclusion, MT2-MMP is involved in GC invasion and metastasis and may serve as an independent prognostic factor for GC patients.
引用
收藏
页码:1985 / 1990
页数:6
相关论文
共 21 条
  • [1] Identification of MMP-15 as an anti-apoptotic factor in cancer cells
    Abraham, R
    Schäfer, J
    Rothe, M
    Bange, J
    Knyazev, P
    Ullrich, A
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (40) : 34123 - 34132
  • [2] The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer
    Al-Batran, S. -E.
    Pauligk, C.
    Wirtz, R.
    Werner, D.
    Steinmetz, K.
    Homann, N.
    Schmalenberg, H.
    Hofheinz, R. -D.
    Hartmann, J. T.
    Atmaca, A.
    Altmannsberger, H. -M.
    Jaeger, E.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (07) : 1699 - 1705
  • [3] [Anonymous], 2020, CA Cancer J Clin, DOI DOI 10.3322/CAAC.21590
  • [4] Benson CS, 2013, DIS MARKERS, V34, P395, DOI [10.1155/2013/420914, 10.3233/DMA-130986]
  • [5] Timeline - Matrix metalloproteinases: a tail of a frog that became a prince
    Brinckerhoff, CE
    Matrisian, LM
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (03) : 207 - 214
  • [6] Chen LJ, 2014, INT J CLIN EXP PATHO, V7, P3469
  • [7] Chen LJ, 2010, ANTICANCER RES, V30, P4363
  • [8] New functions for the matrix metalloproteinases in cancer progression
    Egeblad, M
    Werb, Z
    [J]. NATURE REVIEWS CANCER, 2002, 2 (03) : 161 - 174
  • [9] Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease
    Hammes, Luciano S.
    Tekmal, Rajeshwar Rao
    Naud, Paulo
    Edelweiss, Maria Isabel
    Kirma, Nameer
    Valente, Philip T.
    Syrjanen, Karl J.
    Cunha-Filho, Joao Sabino
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 110 (03) : 445 - 451
  • [10] Matrix Metalloproteinase-14 Is a Negative Prognostic Marker for Patients with Gastric Cancer
    He, Liang
    Chu, Dake
    Li, Xia
    Zheng, Jianyong
    Liu, Shanhong
    Li, Jipeng
    Zhao, Qingchuan
    Ji, Gang
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (05) : 1264 - 1270